Aytu Biopharma, Inc
AYTU Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.90
KIRA · Stoqly’s AI analyst, in plain words
- Aytu Biopharma, Inc had $57.6M of revenue in fiscal 2026, down 13.3% on the year before. Over five years, revenue changed −2.6% a year on average.
- Its operating margin was −14.4%, down 2.7 pts: of every 100 in sales, about −14 is left after running the business.
- Aytu Biopharma, Inc lost $14.3M in fiscal 2026.
- Free cash flow was $3.3M in fiscal 2026, 5.6% of revenue.
- Aytu Biopharma, Inc has $15.4M more cash than debt.
Market cap
—
P/E
—
Revenue
$57.6M
Net income
−$14.3M
Free cash flow
$3.3M
Operating margin
−14.4%
Aytu Biopharma, Inc in 30 seconds · fiscal 2026
Are sales growing?
−13.3%
No. Sales fell 13.3% last year.
Does it make a profit?
−24.8%
No. It lost money last year.
Does profit turn into cash?
5.6%
Partly. 5.6% of sales ends up as free cash.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
What Aytu Biopharma, Inc does
No business description yet.
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 10-K · Sep 22, 2026
- Legal name
- AYTU BIOPHARMA, INC
- CIK
- 0001385818
Aytu Biopharma, Inc · AYTU
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $96.7M | $107M | $65.2M | $66.4M | $57.6M |
| Revenue growth | 47.3% | 11.1% | −39.3% | 1.8% | −13.3% |
| Gross margin | 54.1% | 62.0% | 75.3% | 69.0% | 64.0% |
| Operating margin | −113.7% | −15.9% | −2.4% | −11.8% | −14.4% |
| Net income | −$109M | −$17.1M | −$15.8M | −$13.6M | −$14.3M |
| Net margin | −112.5% | −15.9% | −24.3% | −20.4% | −24.8% |
| Diluted EPS | −$74.01 | −$5.11 | — | — | — |
| Cash | |||||
| Cash from operations | −$28.8M | −$5.1M | −$1.4M | −$1.9M | $3.3M |
| Capital expenditure | $0.0M | — | $0.3M | $0.2M | $0.0M |
| Free cash flow | −$28.8M | — | −$1.7M | −$2.2M | $3.3M |
| FCF margin | −29.8% | — | −2.6% | −3.3% | 5.6% |
| Share count change | −91.2% | 127.2% | — | — | — |
| Debt and strength | |||||
| Cash and short-term investments | $19.4M | $23.0M | $20.0M | $31.0M | $26.3M |
| Debt incl. finance leases | $19.0M | $16.6M | $15.1M | $12.8M | $11.0M |
| Shareholders' equity | $44.3M | $39.4M | $27.7M | $19.0M | $35.3M |
| Net debt / EBITDA | — | — | −0.7x | — | — |
| Current ratio | 0.9x | 1.1x | 1.0x | 1.3x | 1.1x |
| Interest coverage | −122.1x | −3.4x | −0.3x | −2.1x | −4.4x |
| Returns and quality | |||||
| Return on capital | −198.4% | −40.9% | −5.5% | −807.2% | −33.0% |
| Return on equity | −119.6% | −40.8% | −47.2% | −58.1% | −52.6% |
| Piotroski F-score | 4 | 6 | 2 | 4 | 3 |
| Altman Z'' | −11.9 | −7.5 | −8.6 | −8.1 | −10.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Aytu Biopharma, Inc · AYTU
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.90 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001385818). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.